Search - tctmd.com

Displaying 81 - 100 of 128

Sort: Relevancy | Date

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

News Conference News ESC 2017

European Societies Issue New Valvular Heart Disease Guidelines, With Important Shifts

August 27, 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

News Conference News ESC 2017

COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease

August 27, 2017

In Case of Emergency: Don’t Rely on ‘Normal’ Range Assays With DOACs

News Daily News

In Case of Emergency: Don’t Rely on ‘Normal’ Range Assays With DOACs

August 10, 2017

Women With A-fib Less Likely to Get Oral Anticoagulants Regardless of Risk

News Daily News

Women With A-fib Less Likely to Get Oral Anticoagulants Regardless of Risk

August 03, 2017

Inferior Vena Cava Filter Use Fell After FDA Warning but Remains High

News Daily News

Inferior Vena Cava Filter Use Fell After FDA Warning but Remains High

July 12, 2017

Early Cardiology Care Tied to Better Outcomes for New A-fib Patients

News Daily News

Early Cardiology Care Tied to Better Outcomes for New A-fib Patients

June 26, 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

News Daily News

Triple Therapy Not Being Widely Used in A-fib Patients Undergoing PCI

May 23, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

News Daily News

More Excess Bleeding and No Benefit With Triple Therapy After PCI, Meta-analysis Finds

May 05, 2017

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

News Daily News

‘Forgotten’ Patients With Mechanical Heart Valves Undergoing PCI Pose Clinical Conundrum

April 27, 2017

If You Don’t Take Your Stroke Meds, This App Will Tell on You

News Daily News

If You Don’t Take Your Stroke Meds, This App Will Tell on You

April 18, 2017

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

News Daily News

Apixaban Provides ‘Intermediate-Value’ Care, New Economic Analysis Shows

Michael O'Riordan

March 31, 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

News Conference News ACC 2017

RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest

Yael L. Maxwell

March 20, 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

News Conference News ACC 2017

Leaflet Thrombosis Common After Aortic Valve Implant, More So in TAVR Than in Surgery

Michael O'Riordan

March 19, 2017

Live From Washington: ACC 2017, Day Three

News Conference News ACC 2017

Live From Washington: ACC 2017, Day Three

March 19, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

News Daily News

Focused Update to Valve Guidelines Tackles Intermediate-Risk TAVR, Anticoagulation for A-fib

March 15, 2017

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

March 14, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.